PDCD1 and melanoma: For instance, compared to anti-PD-1 alone, the combination of anti-PD-1 and a TNF/TNFR1 gene defect or TNF blockade had better therapeutic benefit (75% survival versus <20% survival) in melanoma and lung cancer mouse models (31).